Home Companies Catalysts Deep Dives

Systemic lupus erythematosus

SLE · Immunology · 5 drugs · 3 indications

Systemic autoimmune disease affecting multiple organs.
Competitive Landscape (5 drugs)
DrugCompanyMechanismModalityRouteStage
GazyvaROG.SWCD20-targeting (glycoengineered)AntibodyIVFILED
Dapirolizumab pegolUCBCD40L inhibitorAntibody fragmentSCPHASE3
IanalumabNVSBAFF receptor antagonistAntibodySCPHASE3
SaphneloAZNType I IFN receptor antagonistAntibodyIVAPPROVED
RinvoqABBVJAK inhibitorSmall moleculeORALAPPROVED
Indications (3)
Systemic Lupus Erythematosus
Gazyva PHASE3Dapirolizumab pegol PHASE3Saphnelo APPROVEDIanalumab PHASE3Rinvoq PHASE3
Cutaneous lupus erythematosus
Lupus nephritis
Dapirolizumab pegol PHASE3Ianalumab PHASE3
Upcoming Catalysts
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Gazyva - Membranous Nephropathy - Ph3 - ToplineCLINICAL
ROG.SWH2 2026
Saphnelo - Lupus Nephritis - Ph3 - ToplineCLINICAL
AZNH2 2026
Saphnelo - Systemic Sclerosis - Ph3 - ToplineCLINICAL
AZNH2 2026
Ianalumab - SLE - Ph3 - Topline (SIRIUS-SLE)CLINICAL
NVSH2 2026
Ianalumab - Sjogren's - Ph3 - ToplineCLINICAL
NVS2027
Data from Supabase · Updated 2026-03-24